Welcome to our dedicated page for Outlook Therapeutics SEC filings (Ticker: OTLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outlook Therapeutics, Inc. (OTLK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Outlook Therapeutics is a biopharmaceutical company focused on ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retina diseases such as wet AMD, and its filings give detailed insight into how this program is progressing through clinical, regulatory, and commercial stages.
Form 8-K current reports are particularly important for OTLK, as they document material events such as the resubmission of the Biologics License Application (BLA) for ONS-5010, FDA classification of the resubmission as a Class 1 review with an associated PDUFA goal date, and the completion of a Type A meeting to discuss a complete response letter (CRL). Other 8-K filings cover executive appointments and departures, stock option inducement grants, and the release of quarterly and annual financial results.
Investors can also use SEC filings to track Outlook Therapeutics’ listing details on The Nasdaq Stock Market LLC under the symbol OTLK, as well as to review risk factor discussions, financial condition, and updates on the NORSE clinical trial program and commercial launch activities referenced in periodic reports. These documents complement the company’s press releases by providing formal, structured descriptions of key events and agreements.
On Stock Titan, Outlook Therapeutics filings are updated as they are made available on EDGAR. AI-powered tools summarize lengthy disclosures, highlight the main points from forms such as 8-Ks and periodic reports, and make it easier to understand technical language around FDA interactions, clinical data references, and compensation arrangements. This allows readers to quickly grasp what each filing means for ONS-5010/LYTENAVA™, the company’s regulatory pathway, and its overall corporate developments.
Outlook Therapeutics, Inc. reported results of its Annual Meeting of Stockholders held on March 10, 2026. Of 73,509,455 common shares outstanding as of the record date, 37,271,431 shares, or approximately 50.70%, were present or represented by proxy, establishing a quorum.
Stockholders elected Class I directors Yezan Haddadin, Faisal G. Sukhtian and Kurt J. Hilzinger to the Board, each to serve until the 2029 Annual Meeting of Stockholders or until a successor is duly elected and qualified. This maintains continuity on the company’s Board of Directors.
Stockholders also ratified the Audit Committee’s selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, with strong support. In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Outlook Therapeutics reported that it has held a Type A meeting with the FDA to discuss the December 30, 2025 Complete Response Letter for its Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg), an investigational treatment for wet age-related macular degeneration (wet AMD) in the United States.
The discussion focused on the FDA’s remaining concern about “substantial evidence of effectiveness” and on possible regulatory paths forward. The company plans to continue dialog with the FDA and is reviewing regulatory options to advance the program toward potential U.S. approval.
Outlook highlighted that ONS-5010 achieved clinically meaningful, statistically significant visual acuity gains in the NORSE TWO Phase 3 trial and that NORSE EIGHT and other data provide confirmatory efficacy and safety evidence, with no safety concerns identified by the FDA. The product already has Marketing Authorizations in the EU and UK and has been launched in Germany, Austria, and the UK for wet AMD, while remaining investigational in the U.S.
Outlook Therapeutics, Inc. received a notice from Nasdaq that its common stock has closed below $1.00 per share for the last 30 consecutive business days, failing to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company’s stock remains listed on the Nasdaq Capital Market for now.
Outlook Therapeutics has 180 calendar days, until August 17, 2026, to regain compliance by having its closing bid price at or above $1.00 per share for at least ten consecutive business days. If it still does not comply, it may qualify for an additional 180-day period if it meets other initial listing standards and notifies Nasdaq that it intends to cure the deficiency, potentially through a reverse stock split.
If the company cannot regain compliance and is not granted or does not succeed in an extension, its common stock could be delisted from the Nasdaq Capital Market. Outlook Therapeutics states that it intends to actively monitor its share price and evaluate options to resolve the deficiency.
Outlook Therapeutics reported a net loss of
Net revenue was negative
The company is commercializing LYTENAVA in Germany and the UK but has received three FDA Complete Response Letters for ONS-5010/LYTENAVA in wet AMD and has requested another Type A meeting to discuss potential regulatory pathways. It also triggered a “Major Trigger Event” under its March 2025 unsecured convertible promissory note, increasing the outstanding balance and resetting the conversion pricing formula.
Outlook Therapeutics reported a GAAP net loss attributable to common stockholders of
Revenue was reduced by a higher returns reserve tied to short-dated LYTENAVA shipments in the UK, but European unit sales of LYTENAVA more than doubled versus the previous three months. As of December 31, 2025, cash and cash equivalents were
Outlook Therapeutics filed an 8-K after submitting a Type A meeting request to the FDA in response to a Complete Response Letter for its Biologics License Application for ONS-5010/LYTENAVA, an ophthalmic bevacizumab candidate for wet age-related macular degeneration.
The FDA’s letter cited a single deficiency, stating there was a lack of substantial evidence of effectiveness and recommending additional confirmatory evidence. The company disagrees, pointing to its NORSE TWO Phase 3 trial, which met its primary and key secondary visual acuity endpoints, and to supportive clinical, mechanistic, and natural history data.
Outlook Therapeutics also highlights NORSE EIGHT, a second Phase 3 study that did not meet its primary endpoint at 8 weeks but showed a positive trajectory and pharmacodynamic evidence through 12 weeks, as well as a favorable safety profile. While ONS-5010 remains investigational in the U.S., the same product, branded as LYTENAVA (bevacizumab gamma), already has marketing authorization and commercial launch for wet AMD in the EU and UK.
Outlook Therapeutics, Inc. received an amended Schedule 13G from Sphera-affiliated investment entities reporting beneficial ownership tied to warrants on its common stock. The group reports 3,153,856 warrants, each currently exercisable into one share of common stock, representing 4.69% of the class.
The percentage is based on 64,114,399 shares of common stock outstanding as of December 16, 2025, plus the warrants held by Sphera-related funds. The reporting persons state the securities are not held to change or influence control of Outlook Therapeutics.
Outlook Therapeutics has released its 2026 proxy statement for the annual stockholders meeting on March 10, 2026 at Cooley LLP’s Chicago office. Stockholders of record on January 12, 2026, when 73,509,455 common shares were outstanding, may vote in person or by proxy.
Investors are asked to elect three Class I directors, ratify the selection of KPMG LLP as independent auditor for the year ending September 30, 2026, and approve an advisory "say‑on‑pay" vote on executive compensation. The board is majority independent and led by an independent chairman, with four standing committees overseeing audit, compensation, nominations and executive matters.
The proxy details executive pay, including a $600,000 base salary and a large stock option grant for CEO Robert C. Jahr, and severance and change‑in‑control protections for senior executives. It also highlights ownership concentration, with GMS Ventures and Investments holding 29,040,929 shares, or 50.3% of common stock, giving it effective control over key votes.
Outlook Therapeutics reported a key regulatory update for ONS-5010 (bevacizumab-vikg). The U.S. Food and Drug Administration acknowledged receipt of the company’s resubmitted Biologics License Application and designated it a Class 1 review, which provides a two-month review period from the date of resubmission.
The FDA established a PDUFA goal date of December 31, 2025. This sets a clear timeline for the agency’s action on the resubmission and marks formal acceptance into the expedited review track associated with a Class 1 review.